Emerging Practices in the Management of Community-Acquired Bacterial Pneumonia

Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-9999-20-018-L01-P), you are NOT allowed to also receive credit for this home-study on-demand web activity.

 

A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) 

 
 View more SIDPEC Activities 
 

Activity Description

Community acquired bacterial pneumonia (CABP) is a common and serious lower respiratory tract infection that causes significant burden on patients and the healthcare system. This continuing education activity will explore the current prevalence and burden of CABP, discuss practice considerations in the use of rapid diagnostics, and examine studies and data surrounding the use of antibiotics currently available as well as emerging agents in the pipeline. A discussion on the latest guideline recommendations along with stratification based on disease severity will provide members of the allied healthcare team with rationale for guiding diagnosis and treatment.

Target Audience

The target audience for this activity includes pharmacists, nurses and physicians.

Learning Objectives

At the completion of this activity, the participant will be able to:

  • Recognize risk factors and emerging resistance trends in community-acquired bacterial pneumonia (CABP).
  • Summarize the 2019 ATS/IDSA guidelines for the diagnosis and treatment of CABP based on severity.
  • Discuss the evolving diagnostic landscape for bacterial respiratory infections and their role in the management of CABP.
  • Compare and contrast current and emerging therapies for treatment of CABP, including dosage forms, mechanisms of action, monitoring parameters, and efficacy data.

Faculty

Michael S. Niederman, MD, MACP, FCCP, FCCM, FERS
Associate Division Chief
Clinical Director, Pulmonary and Critical Care
New York Presbyterian/ Weill Cornell Medical Center
Professor of Clinical Medicine
Weill Cornell Medical College

Alan Gross, PharmD, BCIDP, BCPS
Clinical Associate Professor
University of Illinois at Chicago, College of Pharmacy
Infectious Diseases Pharmacist
University of Illinois Hospital and Health Sciences System

CE Accreditation

Release Date: February 27, 2020
Expiration Date: March 26, 2021

Pharmacists

This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-018-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Nurses

This CE activity is jointly provided by ProCE, Inc. and Wild Iris Medical Education, Inc. This activity provides 1.0 contact hour of nurse CE credit.

Wild Iris Medical Education, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Physicians

AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure

It is the policy of ProCE, Inc. and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.
Dorothy Caputo, MA, BSN, RN - AKH Director of Accreditations and AKH planners and reviewers have no financial relationships to disclose.
Michael S. Niederman, MD, MACP, FCCP, FCCM, FERS and Alan Gross, PharmD, BCIDP, BCPS disclosures will be announced prior to the start of the activity.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Funding

This activity is supported by an educational grant from Paratek Pharmaceuticals.

    

Instructions for Participation and Credit:
For information on applicability and acceptance of continuing education credit for this activity please consult your professional licensing board.

This activity was designed to be completed within the time designated; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online. To receive AMA PRA Category 1 Credit(s)™, you must complete an online post-test and evaluation.

Follow these steps to earn CME credit:
1. Read the target audience, learning objectives and faculty disclosures.
2. Study the educational content online
3. Online, choose the best answer to each posttest question. Complete the evaluation.
4. Print your certificate online

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.